EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Corporate Developments
-
- First patient dosed in Phase 1 clinical trial with EYP-1901 in
-
-
- Total revenues for Full Year 2020 of
- Management to host a conference call and webcast today at 8:30 AM ET
“This year was transformative for EyePoint, across all clinical, financial and commercial fronts, despite the impact of COVID-19 on our business. In
Ms. Lurker continued, “In addition to the advancement of EYP-1901, we have made tremendous progress to improve our balance sheet, including a recent upsized follow-on stock offering with
Corporate Update
- In
February 2021 , the Company completed an upsized underwritten public offering of 10,465,000 shares of its common stock at a public offering price of $11.00 per share, including the exercise in full by the underwriters of their option to purchase up to 1,365,000 additional shares of common stock. The gross proceeds of the offering to the Company were approximately $115.1 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. Cowen and Guggenheim acted as joint book-running managers for the offering. - In December, Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK), made a $15.7 million equity investment in EyePoint, purchasing approximately 3.01 million shares of EyePoint’s common stock.
- Also in December, EyePoint announced a royalty monetization agreement with SWK Holdings Corporation for royalties payable to EyePoint under its license agreement with Alimera Sciences, Inc. for ILUVIEN®. EyePoint received a one-time $16.5 million payment from SWK in exchange for the rights to future royalties payable to EyePoint from the Alimera agreement.
$15 million of the net proceeds from this transaction were applied toward debt obligations with CRG Servicing LLC (CRG). The remaining$1.5 million will be used to advance product pipeline programs.
Commercial Performance in Fourth Quarter 2020
- Net product revenue for YUTIQ and DEXYCU was
$4.0 million and$2.7 million , respectively. - Customer demand of approximately 6,200 units for DEXYCU and approximately 500 units for YUTIQ, increases of 30% and 10%, respectively, over Q3 2020.
- DEXYCU commercial alliance partner, ImprimisRx®, began driving volume through their experienced cataract surgery field force, materially adding to Q4 customer demand.
R&D Highlights
- In
January 2021 , the Company announced that the first patient was dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet AMD. EYP-1901 leverages a bioerodible formulation of the Company’s proprietary Durasert® drug delivery technology platform that has been used in four FDA-approved products, including EyePoint’s YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. - In November, positive data for YUTIQ® and DEXYCU® were featured in four presentations at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Statistically significant efficacy results from the second Phase 3 trial of YUTIQ were presented and post-cataract surgery inflammatory reduction data from a multicenter retrospective study of real-world usage of DEXYCU were also presented.
Review of Results for Fourth Quarter Ended December 31, 2020
For the three months ended December 31, 2020, total net revenue was $7.1 million compared to $8.6 million for the three months ended
Net revenue from licenses, royalties and collaborations for the three months ended December 31, 2020 totaled $0.4 million compared to $0.7 million in the corresponding quarter in 2019.
Operating expenses for the three months ended December 31, 2020 totaled $19.9 million compared to $17.6 million in the prior year period. This increase was driven by a $1.6 million increase in G&A expense, a
Review of Results for the Full Year Ended
For the full year ended December 31, 2020, total net revenue was $34.4 million compared to $20.4 million for the full year ended December 31, 2019. Net product revenue for the full year ended December 31, 2020 was $20.8 million, compared to net product revenues for the full year ended December 31, 2019 of $16.8 million.
Net revenue from royalties and collaborations for the full year ended December 31, 2020 totaled $13.6 million compared to $3.5 million in the corresponding period in 2019.
Operating expenses for the full year ended December 31, 2020 totaled $71.7 million versus $68.2 million in the prior year period. This increase was primarily due to a $3.1 million increase in cost of sales, a $2.8 million increase in G&A expense, a $2.1 million increase in R&D expense partially offset by a $4.5 million decrease in sales and marketing expense. Non-operating expense, net, totaled $8.1 million and net loss was $45.4 million, or $3.54 per share, compared to a net loss of $56.8 million, or $5.44 per share, for the prior year period.
Cash and cash equivalents at December 31, 2020 totaled $44.9 million compared to $22.2 million at December 31, 2019.
Financial Outlook
We expect the cash on hand at
Conference Call Information
EyePoint will host a conference call today, at 8:30 AM ET to discuss the results for the fourth quarter and full year ended December 31, 2020 and recent operational developments. To access the conference call, please dial (877)-303-5828 from the U.S. and Canada or (631)-813-4828 (international) at least 10 minutes prior to the start time and refer to conference ID 1261618. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website.
About EYP-1901
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint’s proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
About
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions, our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
Investors:
SternIR
Direct: 212-698-8700
christina.tartaglia@sternir.com
Media:
201-476-0322
tom@tomgibsoncommunications.com
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except per share data) | ||||||||||||||||
| Three Months Ended |
Twelve Months Ended |
|||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product sales, net | $ | 6,680 | $ | 7,883 | $ | 20,831 | $ | 16,824 | ||||||||
| License and collaboration agreements (including license fees from a related party of |
352 | 236 | 11,942 | 1,361 | ||||||||||||
| Royalty income | 99 | 514 | 1,664 | 2,180 | ||||||||||||
| Total revenues | 7,131 | 8,633 | 34,437 | 20,365 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales, excluding amortization of acquired intangible assets | 2,461 | 1,324 | 5,824 | 2,687 | ||||||||||||
| Research and development | 5,205 | 4,131 | 17,424 | 15,368 | ||||||||||||
| Sales and marketing | 5,810 | 7,399 | 25,293 | 29,772 | ||||||||||||
| General and administrative | 5,777 | 4,149 | 20,726 | 17,939 | ||||||||||||
| Amortization of acquired intangible assets | 615 | 615 | 2,460 | 2,460 | ||||||||||||
| Total operating expenses | 19,868 | 17,618 | 71,727 | 68,226 | ||||||||||||
| Loss from operations | (12,737 | ) | (8,985 | ) | (37,290 | ) | (47,861 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest and other income, net | — | 362 | 58 | 1,054 | ||||||||||||
| Interest expense | (1,827 | ) | (1,787 | ) | (7,257 | ) | (6,176 | ) | ||||||||
| Loss on extinguishment of debt | (905 | ) | — | (905 | ) | (3,810 | ) | |||||||||
| Total other expense, net | (2,732 | ) | (1,425 | ) | (8,104 | ) | (8,932 | ) | ||||||||
| Net loss | $ | (15,469 | ) | $ | (10,410 | ) | $ | (45,394 | ) | $ | (56,793 | ) | ||||
| Net loss per common share - basic and diluted | $ | (1.07 | ) | $ | (0.98 | ) | $ | (3.54 | ) | $ | (5.44 | ) | ||||
| Weighted average common shares outstanding - basic and diluted | 14,501 | 10,688 | 12,836 | 10,431 | ||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (Unaudited) | ||||||||
| (In thousands) | ||||||||
| 2020 | 2019 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 44,909 | $ | 22,214 | ||||
| Accounts and other receivables, net (including due from a related party of |
9,453 | 11,368 | ||||||
| Prepaid expenses and other current assets | 3,419 | 5,997 | ||||||
| Inventory | 5,337 | 2,138 | ||||||
| Total current assets | 63,118 | 41,717 | ||||||
| Property and equipment, net | 630 | 357 | ||||||
| Operating lease right-of-use assets | 2,610 | 3,078 | ||||||
| Intangible assets, net | 25,209 | 27,669 | ||||||
| Restricted cash | 150 | 150 | ||||||
| Total assets | $ | 91,717 | $ | 72,971 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,811 | $ | 4,192 | ||||
| Accrued expenses | 8,445 | 6,832 | ||||||
| Deferred revenue | 945 | 15 | ||||||
| Other current liabilities | 687 | 481 | ||||||
| Total current liabilities | 14,888 | 11,520 | ||||||
| Long-term debt | 37,977 | 47,223 | ||||||
| Deferred revenue, less current portion | 15,616 | — | ||||||
| Operating lease liabilities - noncurrent | 2,330 | 2,898 | ||||||
| Other long-term liabilities | 2,365 | 3,000 | ||||||
| Total liabilities | 73,176 | 64,641 | ||||||
| Stockholders’ equity: | ||||||||
| Capital | 528,380 | 472,776 | ||||||
| Accumulated deficit | (510,680 | ) | (465,286 | ) | ||||
| Accumulated other comprehensive income | 841 | 840 | ||||||
| Total stockholders’ equity | 18,541 | 8,330 | ||||||
| Total liabilities and stockholders’ equity | $ | 91,717 | $ | 72,971 | ||||
Source: EyePoint Pharmaceuticals, Inc.
